Aura Biosciences, Inc. (AURA) Research

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Market snapshot

Symbol
AURA
Price
$6.34
Day change
+0.48%
Market cap
$407.0M
P/E ratio
-3.80x
52-week range
4.73-9.535
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.00

Peer companies

  • Altimmune, Inc. (ALT)
  • Annexon, Inc. (ANNX)
  • DBV Technologies S.A. (DBVT)
  • Design Therapeutics, Inc. (DSGN)
  • enGene Holdings Inc. (ENGN)
  • Korro Bio, Inc. (KRRO)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Quantum-Si incorporated (QSI)

Recent insider activity

  • Gibney Anthony S — S-Sale (12824 shares) on 2026-06-16
  • Bitetti Teresa Marie — A-Award (15000 shares) on 2026-06-11
  • Bitetti Teresa Marie — A-Award (30000 shares) on 2026-06-11
  • Srivastava Sapna — A-Award (15000 shares) on 2026-06-11
  • Srivastava Sapna — A-Award (30000 shares) on 2026-06-11

Open Aura Biosciences, Inc. (AURA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.